Relationship between haemagglutination-inhibiting antibody titres and clinical protection against influenza: development and application of a bayesian random-effects model

Background Antibodies directed against haemagglutinin, measured by the haemagglutination inhibition (HI) assay are essential to protective immunity against influenza infection. An HI titre of 1:40 is generally accepted to correspond to a 50% reduction in the risk of contracting influenza in a suscep...

Full description

Saved in:
Bibliographic Details
Published inBMC medical research methodology Vol. 10; no. 1; p. 18
Main Authors Coudeville, Laurent, Bailleux, Fabrice, Riche, Benjamin, Megas, Françoise, Andre, Philippe, Ecochard, René
Format Journal Article
LanguageEnglish
Published London BioMed Central 08.03.2010
BioMed Central Ltd
Springer Nature B.V
BMC
Subjects
Online AccessGet full text
ISSN1471-2288
1471-2288
DOI10.1186/1471-2288-10-18

Cover

Abstract Background Antibodies directed against haemagglutinin, measured by the haemagglutination inhibition (HI) assay are essential to protective immunity against influenza infection. An HI titre of 1:40 is generally accepted to correspond to a 50% reduction in the risk of contracting influenza in a susceptible population, but limited attempts have been made to further quantify the association between HI titre and protective efficacy. Methods We present a model, using a meta-analytical approach, that estimates the level of clinical protection against influenza at any HI titre level. Source data were derived from a systematic literature review that identified 15 studies, representing a total of 5899 adult subjects and 1304 influenza cases with interval-censored information on HI titre. The parameters of the relationship between HI titre and clinical protection were estimated using Bayesian inference with a consideration of random effects and censorship in the available information. Results A significant and positive relationship between HI titre and clinical protection against influenza was observed in all tested models. This relationship was found to be similar irrespective of the type of viral strain (A or B) and the vaccination status of the individuals. Conclusion Although limitations in the data used should not be overlooked, the relationship derived in this analysis provides a means to predict the efficacy of inactivated influenza vaccines when only immunogenicity data are available. This relationship can also be useful for comparing the efficacy of different influenza vaccines based on their immunological profile.
AbstractList Background Antibodies directed against haemagglutinin, measured by the haemagglutination inhibition (HI) assay are essential to protective immunity against influenza infection. An HI titre of 1:40 is generally accepted to correspond to a 50% reduction in the risk of contracting influenza in a susceptible population, but limited attempts have been made to further quantify the association between HI titre and protective efficacy. Methods We present a model, using a meta-analytical approach, that estimates the level of clinical protection against influenza at any HI titre level. Source data were derived from a systematic literature review that identified 15 studies, representing a total of 5899 adult subjects and 1304 influenza cases with interval-censored information on HI titre. The parameters of the relationship between HI titre and clinical protection were estimated using Bayesian inference with a consideration of random effects and censorship in the available information. Results A significant and positive relationship between HI titre and clinical protection against influenza was observed in all tested models. This relationship was found to be similar irrespective of the type of viral strain (A or B) and the vaccination status of the individuals. Conclusion Although limitations in the data used should not be overlooked, the relationship derived in this analysis provides a means to predict the efficacy of inactivated influenza vaccines when only immunogenicity data are available. This relationship can also be useful for comparing the efficacy of different influenza vaccines based on their immunological profile.
Antibodies directed against haemagglutinin, measured by the haemagglutination inhibition (HI) assay are essential to protective immunity against influenza infection. An HI titre of 1:40 is generally accepted to correspond to a 50% reduction in the risk of contracting influenza in a susceptible population, but limited attempts have been made to further quantify the association between HI titre and protective efficacy.BACKGROUNDAntibodies directed against haemagglutinin, measured by the haemagglutination inhibition (HI) assay are essential to protective immunity against influenza infection. An HI titre of 1:40 is generally accepted to correspond to a 50% reduction in the risk of contracting influenza in a susceptible population, but limited attempts have been made to further quantify the association between HI titre and protective efficacy.We present a model, using a meta-analytical approach, that estimates the level of clinical protection against influenza at any HI titre level. Source data were derived from a systematic literature review that identified 15 studies, representing a total of 5899 adult subjects and 1304 influenza cases with interval-censored information on HI titre. The parameters of the relationship between HI titre and clinical protection were estimated using Bayesian inference with a consideration of random effects and censorship in the available information.METHODSWe present a model, using a meta-analytical approach, that estimates the level of clinical protection against influenza at any HI titre level. Source data were derived from a systematic literature review that identified 15 studies, representing a total of 5899 adult subjects and 1304 influenza cases with interval-censored information on HI titre. The parameters of the relationship between HI titre and clinical protection were estimated using Bayesian inference with a consideration of random effects and censorship in the available information.A significant and positive relationship between HI titre and clinical protection against influenza was observed in all tested models. This relationship was found to be similar irrespective of the type of viral strain (A or B) and the vaccination status of the individuals.RESULTSA significant and positive relationship between HI titre and clinical protection against influenza was observed in all tested models. This relationship was found to be similar irrespective of the type of viral strain (A or B) and the vaccination status of the individuals.Although limitations in the data used should not be overlooked, the relationship derived in this analysis provides a means to predict the efficacy of inactivated influenza vaccines when only immunogenicity data are available. This relationship can also be useful for comparing the efficacy of different influenza vaccines based on their immunological profile.CONCLUSIONAlthough limitations in the data used should not be overlooked, the relationship derived in this analysis provides a means to predict the efficacy of inactivated influenza vaccines when only immunogenicity data are available. This relationship can also be useful for comparing the efficacy of different influenza vaccines based on their immunological profile.
Antibodies directed against haemagglutinin, measured by the haemagglutination inhibition (HI) assay are essential to protective immunity against influenza infection. An HI titre of 1:40 is generally accepted to correspond to a 50% reduction in the risk of contracting influenza in a susceptible population, but limited attempts have been made to further quantify the association between HI titre and protective efficacy. We present a model, using a meta-analytical approach, that estimates the level of clinical protection against influenza at any HI titre level. Source data were derived from a systematic literature review that identified 15 studies, representing a total of 5899 adult subjects and 1304 influenza cases with interval-censored information on HI titre. The parameters of the relationship between HI titre and clinical protection were estimated using Bayesian inference with a consideration of random effects and censorship in the available information. A significant and positive relationship between HI titre and clinical protection against influenza was observed in all tested models. This relationship was found to be similar irrespective of the type of viral strain (A or B) and the vaccination status of the individuals. Although limitations in the data used should not be overlooked, the relationship derived in this analysis provides a means to predict the efficacy of inactivated influenza vaccines when only immunogenicity data are available. This relationship can also be useful for comparing the efficacy of different influenza vaccines based on their immunological profile.
Abstract Background Antibodies directed against haemagglutinin, measured by the haemagglutination inhibition (HI) assay are essential to protective immunity against influenza infection. An HI titre of 1:40 is generally accepted to correspond to a 50% reduction in the risk of contracting influenza in a susceptible population, but limited attempts have been made to further quantify the association between HI titre and protective efficacy. Methods We present a model, using a meta-analytical approach, that estimates the level of clinical protection against influenza at any HI titre level. Source data were derived from a systematic literature review that identified 15 studies, representing a total of 5899 adult subjects and 1304 influenza cases with interval-censored information on HI titre. The parameters of the relationship between HI titre and clinical protection were estimated using Bayesian inference with a consideration of random effects and censorship in the available information. Results A significant and positive relationship between HI titre and clinical protection against influenza was observed in all tested models. This relationship was found to be similar irrespective of the type of viral strain (A or B) and the vaccination status of the individuals. Conclusion Although limitations in the data used should not be overlooked, the relationship derived in this analysis provides a means to predict the efficacy of inactivated influenza vaccines when only immunogenicity data are available. This relationship can also be useful for comparing the efficacy of different influenza vaccines based on their immunological profile.
Antibodies directed against haemagglutinin, measured by the haemagglutination inhibition (HI) assay are essential to protective immunity against influenza infection. An HI titre of 1:40 is generally accepted to correspond to a 50% reduction in the risk of contracting influenza in a susceptible population, but limited attempts have been made to further quantify the association between HI titre and protective efficacy. We present a model, using a meta-analytical approach, that estimates the level of clinical protection against influenza at any HI titre level. Source data were derived from a systematic literature review that identified 15 studies, representing a total of 5899 adult subjects and 1304 influenza cases with interval-censored information on HI titre. The parameters of the relationship between HI titre and clinical protection were estimated using Bayesian inference with a consideration of random effects and censorship in the available information. A significant and positive relationship between HI titre and clinical protection against influenza was observed in all tested models. This relationship was found to be similar irrespective of the type of viral strain (A or B) and the vaccination status of the individuals. Although limitations in the data used should not be overlooked, the relationship derived in this analysis provides a means to predict the efficacy of inactivated influenza vaccines when only immunogenicity data are available. This relationship can also be useful for comparing the efficacy of different influenza vaccines based on their immunological profile.
Background Antibodies directed against haemagglutinin, measured by the haemagglutination inhibition (HI) assay are essential to protective immunity against influenza infection. An HI titre of 1:40 is generally accepted to correspond to a 50% reduction in the risk of contracting influenza in a susceptible population, but limited attempts have been made to further quantify the association between HI titre and protective efficacy. Methods We present a model, using a meta-analytical approach, that estimates the level of clinical protection against influenza at any HI titre level. Source data were derived from a systematic literature review that identified 15 studies, representing a total of 5899 adult subjects and 1304 influenza cases with interval-censored information on HI titre. The parameters of the relationship between HI titre and clinical protection were estimated using Bayesian inference with a consideration of random effects and censorship in the available information. Results A significant and positive relationship between HI titre and clinical protection against influenza was observed in all tested models. This relationship was found to be similar irrespective of the type of viral strain (A or B) and the vaccination status of the individuals. Conclusion Although limitations in the data used should not be overlooked, the relationship derived in this analysis provides a means to predict the efficacy of inactivated influenza vaccines when only immunogenicity data are available. This relationship can also be useful for comparing the efficacy of different influenza vaccines based on their immunological profile.
ArticleNumber 18
Audience Academic
Author Megas, Françoise
Coudeville, Laurent
Bailleux, Fabrice
Riche, Benjamin
Ecochard, René
Andre, Philippe
AuthorAffiliation 1 Sanofi pasteur, 2 avenue Pont Pasteur F-69367 Lyon cedex 07 France
2 Hospices Civils de Lyon, Service de Biostatistique; CNRS, UMR 5558; Université Claude Bernard, Laboratoire Biostatistique Santé, Lyon, France
AuthorAffiliation_xml – name: 1 Sanofi pasteur, 2 avenue Pont Pasteur F-69367 Lyon cedex 07 France
– name: 2 Hospices Civils de Lyon, Service de Biostatistique; CNRS, UMR 5558; Université Claude Bernard, Laboratoire Biostatistique Santé, Lyon, France
Author_xml – sequence: 1
  givenname: Laurent
  surname: Coudeville
  fullname: Coudeville, Laurent
  email: laurent.coudeville@sanofipasteur.com
  organization: Sanofi pasteur
– sequence: 2
  givenname: Fabrice
  surname: Bailleux
  fullname: Bailleux, Fabrice
  organization: Sanofi pasteur
– sequence: 3
  givenname: Benjamin
  surname: Riche
  fullname: Riche, Benjamin
  organization: Hospices Civils de Lyon, Service de Biostatistique; CNRS, UMR 5558, Université Claude Bernard, Laboratoire Biostatistique Santé
– sequence: 4
  givenname: Françoise
  surname: Megas
  fullname: Megas, Françoise
  organization: Sanofi pasteur
– sequence: 5
  givenname: Philippe
  surname: Andre
  fullname: Andre, Philippe
  organization: Sanofi pasteur
– sequence: 6
  givenname: René
  surname: Ecochard
  fullname: Ecochard, René
  organization: Hospices Civils de Lyon, Service de Biostatistique; CNRS, UMR 5558, Université Claude Bernard, Laboratoire Biostatistique Santé
BackLink https://www.ncbi.nlm.nih.gov/pubmed/20210985$$D View this record in MEDLINE/PubMed
BookMark eNqFUk1v1DAQjVAR_YAzNxTBgVNaO4kThwNSVfFRqRISgrM1scdZrxw7xEmr5S_xJ3F2S-lWfCiHxDPvvXjem-PkwHmHSfKcklNKeXVGy5pmec55RklG-aPk6K5ycO_7MDkOYU0IrXlRPUkOc5JT0nB2lPz4jBYm411YmSFtcbpBdOkKsIeus_Nk3LabGbcyrYnHLgU3mdarTTqZacQQzyqV1jgjwabD6CeUCyWFDowLU2qctjO67_AmVXiN1g89umlLg2GwkbaFe51C2sIGgwGXjrHt-wy1jmoh7b1C-zR5rMEGfHb7Pkm-vn_35eJjdvXpw-XF-VUmK9ZMGdXAFaiqJXUNRDFoWcuo1BK5lgohV0XbMEa1LPKSKIqsLCWTGhpaFjkvi5PkcqerPKzFMJoexo3wYMS24MdOwDgZaVHkDYJkNS-pzkuQLaesQFXWpZayUpRHLbLTmt0Amxuw9k6QErFkKJaUxJLStrJQ3u4ow9z2qGQ0awS7d4_9jjMr0flrkXNGa5JHgde3AqP_NmOYRG-CRGvBoZ-DqIuCV5xULCJfPkCu_Ty6aK5oKONVQwmNoFc7UAdx4pimj3-Vi6Q4z_OiJJQ1y61P_4CKj8LeyLi12sT6HuHF_THv5vu1mxHAdgA5-hBG1EKaabsrUdnYf_h39oD3f8dvQwoR6Tocf9vwN8pP9owZvg
CitedBy_id crossref_primary_10_1016_j_vaccine_2015_10_131
crossref_primary_10_1016_j_regg_2018_06_004
crossref_primary_10_4161_hv_6_10_12636
crossref_primary_10_1016_j_vaccine_2018_08_040
crossref_primary_10_1080_23744235_2017_1361547
crossref_primary_10_1093_infdis_jiz004
crossref_primary_10_1111_irv_12706
crossref_primary_10_1371_journal_pbio_3002864
crossref_primary_10_1016_j_vaccine_2016_05_067
crossref_primary_10_1038_s41598_017_05579_4
crossref_primary_10_1016_j_jpeds_2017_08_071
crossref_primary_10_1093_infdis_jiae258
crossref_primary_10_1128_JVI_00285_16
crossref_primary_10_1016_j_cmi_2018_05_002
crossref_primary_10_1016_j_tmaid_2020_101872
crossref_primary_10_1016_j_vaccine_2012_05_060
crossref_primary_10_1016_j_vaccine_2015_11_058
crossref_primary_10_1038_s41467_019_09652_6
crossref_primary_10_1371_journal_pone_0056023
crossref_primary_10_1016_j_vaccine_2017_06_038
crossref_primary_10_1128_CVI_00604_15
crossref_primary_10_1371_journal_pone_0036773
crossref_primary_10_1016_j_cmi_2020_07_033
crossref_primary_10_1097_MD_0000000000038809
crossref_primary_10_1136_bmj_2023_077076
crossref_primary_10_1080_1744666X_2017_1389647
crossref_primary_10_1111_j_1750_2659_2011_00242_x
crossref_primary_10_1093_infdis_jiv332
crossref_primary_10_1093_infdis_jix632
crossref_primary_10_1111_irv_12935
crossref_primary_10_1016_j_vaccine_2015_09_016
crossref_primary_10_1080_21645515_2015_1011987
crossref_primary_10_1016_j_vaccine_2018_07_004
crossref_primary_10_1016_S1473_3099_19_30584_5
crossref_primary_10_1016_j_jinf_2014_09_003
crossref_primary_10_1038_s41467_021_21954_2
crossref_primary_10_1111_irv_12702
crossref_primary_10_1016_j_vaccine_2014_08_031
crossref_primary_10_1097_CM9_0000000000002001
crossref_primary_10_1111_irv_70014
crossref_primary_10_1038_gene_2016_34
crossref_primary_10_1038_ijo_2017_131
crossref_primary_10_1128_JVI_02289_14
crossref_primary_10_1371_journal_pone_0306953
crossref_primary_10_3390_vaccines10050804
crossref_primary_10_1111_irv_12805
crossref_primary_10_1093_infdis_jiw311
crossref_primary_10_3389_fimmu_2022_1081107
crossref_primary_10_1016_j_vaccine_2011_05_001
crossref_primary_10_1016_S1473_3099_11_70156_6
crossref_primary_10_1093_ofid_ofab477
crossref_primary_10_1016_j_coviro_2016_12_004
crossref_primary_10_1080_21645515_2022_2132798
crossref_primary_10_1186_s12951_025_03122_6
crossref_primary_10_1099_vir_0_067488_0
crossref_primary_10_1371_journal_pone_0056700
crossref_primary_10_12688_f1000research_75869_2
crossref_primary_10_3389_fimmu_2023_1143451
crossref_primary_10_1016_j_virol_2015_08_004
crossref_primary_10_1016_j_vaccine_2019_10_046
crossref_primary_10_1002_jmv_29858
crossref_primary_10_1093_jpids_piy057
crossref_primary_10_3389_fimmu_2023_1253626
crossref_primary_10_1016_j_vaccine_2016_01_042
crossref_primary_10_3390_v12090968
crossref_primary_10_1016_j_ijid_2020_06_043
crossref_primary_10_1093_infdis_jiae122
crossref_primary_10_1186_s12879_018_3444_7
crossref_primary_10_1371_journal_pone_0047448
crossref_primary_10_1002_jmv_29743
crossref_primary_10_1371_journal_ppat_1004310
crossref_primary_10_3390_vaccines12091079
crossref_primary_10_12688_f1000research_75869_1
crossref_primary_10_1016_j_msard_2025_106382
crossref_primary_10_1038_s41541_022_00463_3
crossref_primary_10_1017_S0950268816002156
crossref_primary_10_1016_j_vaccine_2023_11_038
crossref_primary_10_1093_infdis_jiae615
crossref_primary_10_1016_j_cell_2023_09_022
crossref_primary_10_1016_j_provac_2014_07_004
crossref_primary_10_1093_ofid_ofae559
crossref_primary_10_1016_j_ijid_2012_05_1025
crossref_primary_10_12938_bmfh_2022_037
crossref_primary_10_1021_jacsau_3c00695
crossref_primary_10_1126_scitranslmed_3008409
crossref_primary_10_1016_j_vaccine_2016_11_013
crossref_primary_10_1016_j_jviromet_2013_03_001
crossref_primary_10_1007_s40506_024_00270_5
crossref_primary_10_1080_21645515_2019_1565269
crossref_primary_10_1038_s41467_021_25713_1
crossref_primary_10_3390_vaccines13030304
crossref_primary_10_4155_bio_11_327
crossref_primary_10_4161_hv_22908
crossref_primary_10_1017_S0950268814000855
crossref_primary_10_3390_vaccines3020373
crossref_primary_10_1128_CVI_00475_15
crossref_primary_10_1097_EDE_0b013e3182302e8e
crossref_primary_10_3390_vaccines10060888
crossref_primary_10_1111_sji_12801
crossref_primary_10_3390_vaccines10111924
crossref_primary_10_1016_j_vaccine_2011_07_050
crossref_primary_10_3390_vaccines8020325
crossref_primary_10_3390_v16030479
crossref_primary_10_1016_j_vaccine_2022_03_065
crossref_primary_10_3389_fimmu_2019_00611
crossref_primary_10_1016_j_stem_2025_01_014
crossref_primary_10_1016_j_vaccine_2014_08_068
crossref_primary_10_1186_1471_2288_13_29
crossref_primary_10_3390_vaccines12030303
crossref_primary_10_1016_j_vaccine_2015_10_119
crossref_primary_10_1016_j_vaccine_2010_08_102
crossref_primary_10_1016_j_epidem_2015_06_001
crossref_primary_10_1016_j_mehy_2023_111135
crossref_primary_10_3390_v14091937
crossref_primary_10_1016_j_jinf_2019_11_024
crossref_primary_10_1111_j_1750_2659_2011_00229_x
crossref_primary_10_1016_S1473_3099_10_70296_6
crossref_primary_10_1371_journal_pone_0140702
crossref_primary_10_1038_s41541_024_00891_3
crossref_primary_10_1016_j_vaccine_2019_08_071
crossref_primary_10_1186_s12874_015_0096_9
crossref_primary_10_1038_s41541_024_00937_6
crossref_primary_10_1155_2018_7251793
crossref_primary_10_3390_vaccines6030039
crossref_primary_10_1080_21645515_2017_1338547
crossref_primary_10_1038_s41591_021_01377_8
crossref_primary_10_1371_journal_pone_0015559
crossref_primary_10_1093_cid_cit048
crossref_primary_10_1093_infdis_jiu186
crossref_primary_10_1016_j_coi_2018_05_010
crossref_primary_10_1111_imr_12514
crossref_primary_10_1038_s41467_023_44668_z
crossref_primary_10_1051_medsci_2019266
crossref_primary_10_1038_s41541_017_0012_x
crossref_primary_10_1093_crocol_otaa086
crossref_primary_10_1186_s12917_015_0586_3
crossref_primary_10_1371_journal_pcbi_1006377
crossref_primary_10_1016_j_micpath_2012_11_013
crossref_primary_10_1093_ofid_ofv067
crossref_primary_10_3390_vaccines10040593
crossref_primary_10_1128_mBio_00417_16
crossref_primary_10_1371_journal_pone_0024384
crossref_primary_10_1101_cshperspect_a038653
crossref_primary_10_1186_1742_4933_11_10
crossref_primary_10_1016_j_epidem_2017_03_003
crossref_primary_10_1093_ibd_izz164
crossref_primary_10_1371_journal_pone_0028063
crossref_primary_10_1016_j_vaccine_2024_126579
crossref_primary_10_4161_hv_8_1_18214
crossref_primary_10_1089_vim_2013_0111
crossref_primary_10_1016_j_vaccine_2012_09_005
crossref_primary_10_1016_j_vaccine_2023_09_025
crossref_primary_10_3390_ijerph19159425
crossref_primary_10_1016_j_vaccine_2018_05_117
crossref_primary_10_1016_j_vaccine_2022_04_049
crossref_primary_10_1093_infdis_jiaa293
crossref_primary_10_1586_erv_13_35
crossref_primary_10_1093_nar_gkt1133
crossref_primary_10_1016_j_trim_2019_01_001
crossref_primary_10_1371_journal_pone_0246613
crossref_primary_10_1038_s41541_022_00492_y
crossref_primary_10_1586_14760584_2016_1164046
crossref_primary_10_2139_ssrn_4751438
crossref_primary_10_3390_vaccines12121307
crossref_primary_10_1002_elps_202100269
crossref_primary_10_1073_pnas_1303117110
crossref_primary_10_1016_j_vaccine_2020_01_088
crossref_primary_10_1016_j_bbi_2013_10_003
crossref_primary_10_1016_j_jia_2023_11_007
crossref_primary_10_3390_vaccines9030257
crossref_primary_10_1038_s41467_022_29310_8
crossref_primary_10_3390_v14081692
crossref_primary_10_1111_ajt_15296
crossref_primary_10_1016_j_vaccine_2010_10_009
crossref_primary_10_3201_eid2805_211965
crossref_primary_10_1128_CVI_05528_11
crossref_primary_10_3390_vaccines6020027
crossref_primary_10_1016_j_vaccine_2011_11_114
crossref_primary_10_1093_infdis_jiy696
crossref_primary_10_1172_JCI122895
crossref_primary_10_1038_s41541_021_00377_6
crossref_primary_10_1038_s41591_019_0463_x
crossref_primary_10_2807_1560_7917_ES2015_20_2_21011
crossref_primary_10_1111_irv_12411
crossref_primary_10_1007_s00103_012_1590_4
crossref_primary_10_3390_vaccines12101100
crossref_primary_10_1186_s13063_017_1808_8
crossref_primary_10_1080_21645515_2016_1219809
crossref_primary_10_1038_s41564_024_01732_8
crossref_primary_10_4049_jimmunol_1701276
crossref_primary_10_1126_sciadv_ads1267
crossref_primary_10_1016_j_virusres_2013_05_006
crossref_primary_10_1016_j_vaccine_2019_12_037
crossref_primary_10_1146_annurev_immunol_032414_112315
crossref_primary_10_1097_QAD_0b013e32835ab5b2
crossref_primary_10_1371_journal_pone_0100926
crossref_primary_10_7554_eLife_90091
crossref_primary_10_1093_infdis_jis360
crossref_primary_10_1111_1750_3841_15675
crossref_primary_10_12771_emj_2024_e35
crossref_primary_10_1016_j_vaccine_2015_04_059
crossref_primary_10_1007_s10238_023_01203_0
crossref_primary_10_1016_j_vaccine_2018_11_061
crossref_primary_10_4161_hv_8_1_18011
crossref_primary_10_1128_CVI_00297_16
crossref_primary_10_1098_rstb_2012_0200
crossref_primary_10_1128_mBio_00012_12
crossref_primary_10_1016_j_vaccine_2020_11_032
crossref_primary_10_1136_annrheumdis_2014_207191
crossref_primary_10_1038_s41598_024_83026_x
crossref_primary_10_1016_j_vaccine_2014_05_027
crossref_primary_10_1016_j_it_2016_05_005
crossref_primary_10_1016_j_vaccine_2012_07_039
crossref_primary_10_1586_erv_11_101
crossref_primary_10_1016_j_vaccine_2025_126802
crossref_primary_10_1182_bloodadvances_2020003880
crossref_primary_10_1371_journal_pcbi_1007294
crossref_primary_10_1016_S0140_6736_10_62228_3
crossref_primary_10_14745_ccdr_v37i00a04
crossref_primary_10_1016_j_cmi_2019_06_013
crossref_primary_10_4161_hv_25580
crossref_primary_10_1016_j_vaccine_2015_03_031
crossref_primary_10_1093_cid_cix900
crossref_primary_10_1371_journal_pcbi_1006505
crossref_primary_10_1371_journal_pone_0210124
crossref_primary_10_3201_eid2404_171995
crossref_primary_10_1093_infdis_jiz327
crossref_primary_10_1371_journal_pcbi_1007840
crossref_primary_10_1371_journal_ppat_1006432
crossref_primary_10_1186_s12974_023_02945_0
crossref_primary_10_1080_22221751_2023_2290838
crossref_primary_10_1093_cid_ciaa1927
crossref_primary_10_3390_vaccines7010030
crossref_primary_10_1016_j_vaccine_2011_05_040
crossref_primary_10_1016_j_vaccine_2014_05_045
crossref_primary_10_1128_JVI_01202_17
crossref_primary_10_3390_vaccines12111275
crossref_primary_10_7554_eLife_62105
crossref_primary_10_1172_JCI148763
crossref_primary_10_1093_infdis_jiy013
crossref_primary_10_1186_s12879_019_4049_5
crossref_primary_10_1089_hum_2018_102
crossref_primary_10_3390_v13020199
crossref_primary_10_1371_journal_pone_0059077
crossref_primary_10_1016_j_vaccine_2015_08_065
crossref_primary_10_1371_journal_pone_0172008
crossref_primary_10_1586_eri_11_51
crossref_primary_10_1371_journal_pcbi_1012893
crossref_primary_10_1111_irv_12452
crossref_primary_10_1111_ajt_16295
crossref_primary_10_3390_vaccines2040707
crossref_primary_10_14776_piv_2019_26_e18
crossref_primary_10_4161_hv_25363
crossref_primary_10_1093_ofid_ofz383
crossref_primary_10_1126_science_1256427
crossref_primary_10_1080_21645515_2015_1011562
crossref_primary_10_1016_j_vaccine_2017_01_026
crossref_primary_10_1080_21645515_2017_1413518
crossref_primary_10_1136_jitc_2021_003428
crossref_primary_10_1371_journal_pone_0253028
crossref_primary_10_1371_journal_pone_0181738
crossref_primary_10_1186_1471_2458_12_417
crossref_primary_10_3390_microorganisms9112323
crossref_primary_10_3390_pathogens13020097
crossref_primary_10_1093_infdis_jit372
crossref_primary_10_1016_j_vaccine_2020_01_022
crossref_primary_10_1002_jmv_29266
crossref_primary_10_3390_vaccines12080943
crossref_primary_10_4178_epih_e2021076
crossref_primary_10_3390_vaccines7040215
crossref_primary_10_3390_pathogens8040238
crossref_primary_10_1038_s41392_022_00920_4
crossref_primary_10_3390_vaccines9121465
Cites_doi 10.1017/S0022172400053158
10.1002/sim.4780110204
10.1016/S0140-6736(06)68656-X
10.1017/S0022172400028990
10.1093/infdis/116.4.425
10.1214/07-AOAS132
10.1086/522428
10.1016/j.virusres.2004.02.025
10.1371/journal.pmed.0040218
10.1080/01621459.1987.10478458
10.1016/j.vaccine.2008.04.016
10.1111/1467-9868.00353
10.1093/biostatistics/1.1.49
10.4049/jimmunol.176.10.6333
10.1001/jama.1957.02980290006002
10.1016/j.virusres.2004.02.024
10.1017/S0022172400022610
10.1002/sim.2282
10.1016/S0264-410X(96)00302-7
10.1016/0264-410X(94)90056-6
10.1016/S0264-410X(03)00073-2
10.1002/sim.3122
10.1017/S0022172400063907
10.2307/1390675
10.1097/00006454-200101000-00013
10.1017/S0022172400028989
10.1016/S0197-2456(01)00153-2
10.1016/j.biologicals.2009.02.002
10.1002/sim.4780080407
10.1136/pgmj.49.569.159
10.1023/A:1008929526011
10.1201/9781482276596
10.1191/0962280204sm362ra
10.1093/oxfordjournals.aje.a112029
10.1093/oxfordjournals.aje.a113408
ContentType Journal Article
Copyright Coudeville et al; licensee BioMed Central Ltd. 2010
COPYRIGHT 2010 BioMed Central Ltd.
2010 Coudeville et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright ©2010 Coudeville et al; licensee BioMed Central Ltd. 2010 Coudeville et al; licensee BioMed Central Ltd.
Copyright_xml – notice: Coudeville et al; licensee BioMed Central Ltd. 2010
– notice: COPYRIGHT 2010 BioMed Central Ltd.
– notice: 2010 Coudeville et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
– notice: Copyright ©2010 Coudeville et al; licensee BioMed Central Ltd. 2010 Coudeville et al; licensee BioMed Central Ltd.
DBID C6C
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7X7
7XB
88E
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
FYUFA
GHDGH
K9.
M0S
M1P
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
PRINS
7X8
5PM
ADTOC
UNPAY
DOA
DOI 10.1186/1471-2288-10-18
DatabaseName Springer Nature Open Access Journals
CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
ProQuest Central
ProQuest One Community College
ProQuest Central
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Health & Medical Complete (Alumni)
ProQuest Health & Medical Collection
Medical Database
ProQuest Central Premium
ProQuest One Academic
ProQuest Publicly Available Content Database
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
PubMed Central (Full Participant titles)
Unpaywall for CDI: Periodical Content
Unpaywall
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Central China
ProQuest Central
ProQuest Health & Medical Research Collection
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
Health & Medical Research Collection
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList
MEDLINE - Academic
MEDLINE


Publicly Available Content Database

Database_xml – sequence: 1
  dbid: C6C
  name: SpringerOpen Free (Free internet resource, activated by CARLI)
  url: http://www.springeropen.com/
  sourceTypes: Publisher
– sequence: 2
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 3
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 4
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 5
  dbid: UNPAY
  name: Unpaywall
  url: https://proxy.k.utb.cz/login?url=https://unpaywall.org/
  sourceTypes: Open Access Repository
– sequence: 6
  dbid: BENPR
  name: ProQuest Central
  url: http://www.proquest.com/pqcentral?accountid=15518
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1471-2288
EndPage 18
ExternalDocumentID oai_doaj_org_article_29eac57841f24acb8153ed474fcc6d18
10.1186/1471-2288-10-18
PMC2851702
2559563681
A223401598
20210985
10_1186_1471_2288_10_18
Genre Meta-Analysis
Journal Article
GeographicLocations France
GeographicLocations_xml – name: France
GroupedDBID ---
0R~
23N
2VQ
2WC
4.4
53G
5VS
6J9
6PF
7X7
88E
8FI
8FJ
AAFWJ
AAJSJ
AASML
AAWTL
ABDBF
ABUWG
ACGFO
ACGFS
ACIHN
ACUHS
ADBBV
ADRAZ
ADUKV
AEAQA
AENEX
AFKRA
AFPKN
AHBYD
AHMBA
AHSBF
AHYZX
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AMTXH
AOIJS
BAPOH
BAWUL
BCNDV
BENPR
BFQNJ
BMC
BPHCQ
BVXVI
C1A
C6C
CCPQU
CS3
DIK
DU5
E3Z
EAD
EAP
EAS
EBD
EBLON
EBS
EJD
EMB
EMK
EMOBN
ESX
F5P
FYUFA
GROUPED_DOAJ
GX1
H13
HMCUK
HYE
IAO
IHR
INH
INR
IPNFZ
ITC
KQ8
M1P
M48
MK0
M~E
O5R
O5S
OK1
OVT
P2P
PGMZT
PHGZM
PHGZT
PIMPY
PJZUB
PPXIY
PQQKQ
PROAC
PSQYO
PUEGO
RBZ
RIG
RNS
ROL
RPM
RSV
SMD
SOJ
SV3
TR2
TUS
UKHRP
W2D
WOQ
WOW
XSB
AAYXX
CITATION
ALIPV
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7XB
8FK
AZQEC
DWQXO
K9.
PKEHL
PQEST
PQUKI
PRINS
7X8
5PM
ADTOC
AFFHD
UNPAY
ID FETCH-LOGICAL-c659t-1fa8dad6b077a0d5ab5b51cfce8fcdea2d3b9551fc3240d1e544c5cfa91432843
IEDL.DBID M48
ISSN 1471-2288
IngestDate Fri Oct 03 12:48:07 EDT 2025
Wed Oct 29 11:47:02 EDT 2025
Tue Sep 30 16:54:24 EDT 2025
Thu Sep 04 15:46:15 EDT 2025
Tue Oct 07 05:21:59 EDT 2025
Mon Oct 20 22:32:44 EDT 2025
Mon Oct 20 16:32:45 EDT 2025
Mon Jul 21 06:04:09 EDT 2025
Thu Apr 24 22:51:16 EDT 2025
Wed Oct 01 05:06:50 EDT 2025
Sat Sep 06 07:28:54 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords Haemagglutination Inhibition
Vaccine Strain
Influenza Vaccine
Vaccine Efficacy
Influenza
Language English
License http://creativecommons.org/licenses/by/2.0
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
cc-by
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c659t-1fa8dad6b077a0d5ab5b51cfce8fcdea2d3b9551fc3240d1e544c5cfa91432843
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ObjectType-Undefined-3
OpenAccessLink https://doaj.org/article/29eac57841f24acb8153ed474fcc6d18
PMID 20210985
PQID 915869101
PQPubID 42579
PageCount 1
ParticipantIDs doaj_primary_oai_doaj_org_article_29eac57841f24acb8153ed474fcc6d18
unpaywall_primary_10_1186_1471_2288_10_18
pubmedcentral_primary_oai_pubmedcentral_nih_gov_2851702
proquest_miscellaneous_733868065
proquest_journals_915869101
gale_infotracmisc_A223401598
gale_infotracacademiconefile_A223401598
pubmed_primary_20210985
crossref_citationtrail_10_1186_1471_2288_10_18
crossref_primary_10_1186_1471_2288_10_18
springer_journals_10_1186_1471_2288_10_18
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2010-03-08
PublicationDateYYYYMMDD 2010-03-08
PublicationDate_xml – month: 03
  year: 2010
  text: 2010-03-08
  day: 08
PublicationDecade 2010
PublicationPlace London
PublicationPlace_xml – name: London
– name: England
PublicationTitle BMC medical research methodology
PublicationTitleAbbrev BMC Med Res Methodol
PublicationTitleAlternate BMC Med Res Methodol
PublicationYear 2010
Publisher BioMed Central
BioMed Central Ltd
Springer Nature B.V
BMC
Publisher_xml – name: BioMed Central
– name: BioMed Central Ltd
– name: Springer Nature B.V
– name: BMC
References Tanner, Wong (CR19) 1987; 82
Plotkin (CR26) 2001; 20
Farnik, Bruj (CR38) 1966; 116
Salk, Menke, Francis (CR8) 1945; 42
Freedman, Graubard, Schatzkin (CR11) 1992; 11
Hannoun, Megas, Piercy (CR6) 2004; 103
De Gruttola, Clax, DeMets, Downing, Ellenberg, Friedman (CR12) 2001; 22
Evans (CR37) 1975; 48
Brooks, Gelman (CR21) 1998; 7
Gilbert, Qin, Self (CR7) 2008; 27
Nauta, Beyer, Osterhaus (CR28) 2009; 37
Clark, Potter, Jennings, Nicholl, Langrick, Schild (CR33) 1983; 90
Potter, Jennings, Nicholson, Tyrrell, Dickinson (CR43) 1977; 79
Hirota, Kaji, Ide, Kajiwara, Kataoka, Goto (CR24) 1997; 15
Goodeve, Potter, Clark, Jennings, Schild, Yetts (CR40) 1983; 90
Buyse, Molenberghs, Burzykowski, Renard, Geys (CR13) 2000; 1
Kohberger, Jemiolo, Noriega (CR17) 2008; 26
Bresson, Perronne, Launay, Gerdil, Saville, Wood (CR31) 2006; 367
McElhaney, Xie, Hager, Barry, Wang, Kleppinger (CR27) 2006; 176
Dunning (CR16) 2006; 25
Riley, Wu, Leung (CR9) 2007; 4
Molenberghs, Burzykowski, Alonso, Buyse (CR15) 2004; 13
(CR3) 1997
Wood, Levandowski (CR4) 2003; 21
Lunn, Thomas, Best, Spiegelhalter (CR20) 2000; 10
Wood, Gaines-Das, Taylor, Chakraverty (CR29) 1994; 12
Spiegelhalter, Best, Carlin, Linde (CR23) 2002; 64
Gupta, Nadarajah (CR22) 2004
Greenberg, Couch, Kasel (CR41) 1974; 100
Prentice (CR10) 1989; 8
Eaton, Meiklejohn (CR36) 1945; 42
(CR1) 2008
Palmer, Dowdle, Coleman, Schild (CR2) 1975
Qin, Gilbert, Follman, Li (CR18) 2008; 2
Dowdle, Coleman, Mostow, Kaye, Schoenbaum (CR35) 1973; 49
de Jong, Palache, Beyer, Rimmelzwaan, Boon, Osterhaus (CR25) 2003; 115
Qin, Gilbert, Corey, McElrath, Self (CR14) 2007; 196
Bell, Ward, Kapikian, Shelokov, Reichelderfer, Huebner (CR32) 1957; 165
Fox, Cooney, Hall, Foy (CR39) 1982; 116
Hobson, Curry, Beare, Ward-Gardner (CR5) 1972; 70
Beyer, Palache, Luchters, Nauta, Osterhaus (CR30) 2004; 103
Clark, Potter, Jennings, Nicholl, Langrick, Schild (CR34) 1983; 90
Meiklejohn, Weiss, Shragg, Lennette (CR42) 1952; 55
Y Hirota (421_CR24) 1997; 15
LS Freedman (421_CR11) 1992; 11
JE McElhaney (421_CR27) 2006; 176
D Hobson (421_CR5) 1972; 70
RC Kohberger (421_CR17) 2008; 26
MD Eaton (421_CR36) 1945; 42
AS Evans (421_CR37) 1975; 48
G Molenberghs (421_CR15) 2004; 13
AK Gupta (421_CR22) 2004
AJ Dunning (421_CR16) 2006; 25
DJ Lunn (421_CR20) 2000; 10
A Goodeve (421_CR40) 1983; 90
CW Potter (421_CR43) 1977; 79
S Riley (421_CR9) 2007; 4
JP Fox (421_CR39) 1982; 116
Committee for Proprietary Medicinal Products (CPMP) (421_CR3) 1997
C Hannoun (421_CR6) 2004; 103
L Qin (421_CR14) 2007; 196
WR Dowdle (421_CR35) 1973; 49
D Spiegelhalter (421_CR23) 2002; 64
A Clark (421_CR34) 1983; 90
JM Wood (421_CR4) 2003; 21
JA Bell (421_CR32) 1957; 165
L Qin (421_CR18) 2008; 2
JL Bresson (421_CR31) 2006; 367
G Meiklejohn (421_CR42) 1952; 55
JE Salk (421_CR8) 1945; 42
DF Palmer (421_CR2) 1975
MA Tanner (421_CR19) 1987; 82
PB Gilbert (421_CR7) 2008; 27
J Farnik (421_CR38) 1966; 116
SP Brooks (421_CR21) 1998; 7
JC de Jong (421_CR25) 2003; 115
JJ Nauta (421_CR28) 2009; 37
WE Beyer (421_CR30) 2004; 103
SB Greenberg (421_CR41) 1974; 100
WHO (421_CR1) 2008
A Clark (421_CR33) 1983; 90
RL Prentice (421_CR10) 1989; 8
M Buyse (421_CR13) 2000; 1
JM Wood (421_CR29) 1994; 12
SA Plotkin (421_CR26) 2001; 20
VG De Gruttola (421_CR12) 2001; 22
16158409 - Stat Med. 2006 May 15;25(9):1485-97
6822725 - J Hyg (Lond). 1983 Feb;90(1):107-15
4479059 - Am J Epidemiol. 1974 Sep;100(3):209-15
11578783 - Control Clin Trials. 2001 Oct;22(5):485-502
17579511 - PLoS Med. 2007 Jun;4(6):e218
19268607 - Biologicals. 2009 Aug;37(4):216-21
15163500 - Virus Res. 2004 Jul;103(1-2):125-32
16670345 - J Immunol. 2006 May 15;176(10):6333-9
12933525 - Biostatistics. 2000 Mar;1(1):49-67
18495303 - Vaccine. 2008 Jun 25;26(27-28):3516-21
15198486 - Stat Methods Med Res. 2004 Jun;13(3):177-206
169640 - Yale J Biol Med. 1975 Jul;48(3):201-9
16714186 - Lancet. 2006 May 20;367(9523):1657-64
9261942 - Vaccine. 1997 Jun;15(9):962-7
11176570 - Pediatr Infect Dis J. 2001 Jan;20(1):63-75
1579756 - Stat Med. 1992 Jan 30;11(2):167-78
2727467 - Stat Med. 1989 Apr;8(4):431-40
15163501 - Virus Res. 2004 Jul;103(1-2):133-8
270523 - J Hyg (Lond). 1977 Dec;79(3):321-32
8147099 - Vaccine. 1994 Feb;12(2):167-74
15088777 - Dev Biol (Basel). 2003;115:63-73
5928620 - J Infect Dis. 1966 Oct;116(4):425-8
4803439 - Postgrad Med J. 1973 Mar;49(569):159-63
17979212 - Stat Med. 2008 Oct 15;27(23):4758-78
7114034 - Am J Epidemiol. 1982 Aug;116(2):228-42
14885161 - Am J Hyg. 1952 Jan;55(1):1-11
19079758 - Ann Appl Stat. 2008 Mar;2(1):386-407
17922394 - J Infect Dis. 2007 Nov 1;196(9):1304-12
4509641 - J Hyg (Lond). 1972 Dec;70(4):767-77
13475045 - J Am Med Assoc. 1957 Nov 16;165(11):1366-73
6863910 - J Hyg (Lond). 1983 Jun;90(3):361-70
6863909 - J Hyg (Lond). 1983 Jun;90(3):351-9
12686095 - Vaccine. 2003 May 1;21(16):1786-8
References_xml – volume: 79
  start-page: 321
  year: 1977
  end-page: 332
  ident: CR43
  article-title: Immunity to attenuated influenza virus WRL 105 infection induced by heterologous, inactivated influenza A virus vaccines
  publication-title: J Hyg (Lond)
  doi: 10.1017/S0022172400053158
– volume: 11
  start-page: 167
  year: 1992
  end-page: 178
  ident: CR11
  article-title: Statistical validation of intermediate endpoints for chronic diseases
  publication-title: Stat Med
  doi: 10.1002/sim.4780110204
– volume: 367
  start-page: 1657
  year: 2006
  end-page: 1664
  ident: CR31
  article-title: Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial
  publication-title: Lancet
  doi: 10.1016/S0140-6736(06)68656-X
– volume: 90
  start-page: 361
  year: 1983
  end-page: 370
  ident: CR34
  article-title: A comparison of live and inactivated influenza A (H1N1) virus vaccines. 2. Long-term immunity
  publication-title: J Hyg (Lond)
  doi: 10.1017/S0022172400028990
– volume: 116
  start-page: 228
  year: 1982
  end-page: 242
  ident: CR39
  article-title: Influenzavirus infections in Seattle families, 1975-1979. II. Pattern of infection in invaded households and relation of age and prior antibody to occurrence of infection and related illness
  publication-title: Am J Epidemiol
– volume: 116
  start-page: 425
  year: 1966
  end-page: 428
  ident: CR38
  article-title: An outbreak of influenza A2 in a population with a known antibody profile
  publication-title: J Infect Dis
  doi: 10.1093/infdis/116.4.425
– volume: 2
  start-page: 386
  year: 2008
  end-page: 407
  ident: CR18
  article-title: Assessing surrogate endpoints in vaccine trials with case-cohort sampling and the cox model
  publication-title: The annals of applied statistics
  doi: 10.1214/07-AOAS132
– volume: 196
  start-page: 1304
  year: 2007
  end-page: 1312
  ident: CR14
  article-title: A framework for assessing immunological correlates of protection in vaccine trials
  publication-title: J Infect Dis
  doi: 10.1086/522428
– volume: 103
  start-page: 133
  year: 2004
  end-page: 138
  ident: CR6
  article-title: Immunogenicity and protective efficacy of influenza vaccination
  publication-title: Virus Res
  doi: 10.1016/j.virusres.2004.02.025
– volume: 4
  start-page: e218
  year: 2007
  ident: CR9
  article-title: Optimizing the dose of pre-pandemic influenza vaccines to reduce the infection attack rate
  publication-title: PLoS Med
  doi: 10.1371/journal.pmed.0040218
– volume: 82
  start-page: 528
  year: 1987
  end-page: 550
  ident: CR19
  article-title: The calculation of posterior distributions by data augmentation
  publication-title: J Am Stat Assoc
  doi: 10.1080/01621459.1987.10478458
– volume: 26
  start-page: 3516
  year: 2008
  end-page: 3521
  ident: CR17
  article-title: Prediction of pertussis vaccine efficacy using a correlates of protection model
  publication-title: Vaccine
  doi: 10.1016/j.vaccine.2008.04.016
– volume: 64
  start-page: 583
  year: 2002
  end-page: 639
  ident: CR23
  article-title: Bayesian measures of model complexity and fit (with discussion)
  publication-title: Journal of the Royal Statistical Society, Series B (Statistical Methodology)
  doi: 10.1111/1467-9868.00353
– volume: 48
  start-page: 201
  year: 1975
  end-page: 209
  ident: CR37
  article-title: Serologic studies of acute respiratory infections in military personnel
  publication-title: Yale J Biol Med
– volume: 1
  start-page: 49
  year: 2000
  end-page: 67
  ident: CR13
  article-title: The validation of surrogate endpoints in meta-analyses of randomized experiments
  publication-title: Biostatistics
  doi: 10.1093/biostatistics/1.1.49
– year: 2008
  ident: CR1
  article-title: Influenza factsheet
  publication-title: Factsheet number 211
– volume: 176
  start-page: 6333
  year: 2006
  end-page: 6339
  ident: CR27
  article-title: T cell responses are better correlates of vaccine protection in the elderly
  publication-title: J Immunol
  doi: 10.4049/jimmunol.176.10.6333
– volume: 165
  start-page: 1366
  year: 1957
  end-page: 1373
  ident: CR32
  article-title: Artificially induced Asian influenza in vaccinated and unvaccinated volunteers
  publication-title: J Am Med Assoc
  doi: 10.1001/jama.1957.02980290006002
– volume: 103
  start-page: 125
  year: 2004
  end-page: 132
  ident: CR30
  article-title: Seroprotection rate, mean fold increase, seroconversion rate: which parameter adequately expresses seroresponse to influenza vaccination?
  publication-title: Virus Res
  doi: 10.1016/j.virusres.2004.02.024
– volume: 55
  start-page: 1
  year: 1952
  end-page: 11
  ident: CR42
  article-title: Evaluation of monovalent influenza virus vaccines. I. Observations on antibody response following vaccination
  publication-title: Am J Hyg
– volume: 70
  start-page: 767
  year: 1972
  end-page: 777
  ident: CR5
  article-title: The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses
  publication-title: J Hyg (Lond)
  doi: 10.1017/S0022172400022610
– volume: 100
  start-page: 209
  year: 1974
  end-page: 215
  ident: CR41
  article-title: An outbreak of an influenza type A variant in a closed population: The effect of homologous and heterologous antibody on infection and illness
  publication-title: Am J Epidemiol
– year: 1997
  ident: CR3
  article-title: Note for Guidance on Harmonisation of Requirements for Influenza Vaccines
  publication-title: EMEA
– year: 1975
  ident: CR2
  publication-title: Advanced laboratory technicals for immunological diagnostic
– volume: 25
  start-page: 1485
  year: 2006
  end-page: 1497
  ident: CR16
  article-title: A model for immunological correlates of protection
  publication-title: Stat Med
  doi: 10.1002/sim.2282
– volume: 15
  start-page: 962
  year: 1997
  end-page: 967
  ident: CR24
  article-title: Antibody efficacy as a keen index to evaluate influenza vaccine effectiveness
  publication-title: Vaccine
  doi: 10.1016/S0264-410X(96)00302-7
– volume: 42
  start-page: 57
  year: 1945
  end-page: 93
  ident: CR8
  article-title: A clinical, epidemiological and immunological evaluation of vaccination against epidemic influenza
  publication-title: Am J Hyg
– volume: 12
  start-page: 167
  year: 1994
  end-page: 174
  ident: CR29
  article-title: Comparison of influenza serological techniques by international collaborative study
  publication-title: Vaccine
  doi: 10.1016/0264-410X(94)90056-6
– volume: 21
  start-page: 1786
  year: 2003
  end-page: 1788
  ident: CR4
  article-title: The influenza vaccine licensing process
  publication-title: Vaccine
  doi: 10.1016/S0264-410X(03)00073-2
– volume: 27
  start-page: 4758
  year: 2008
  end-page: 4778
  ident: CR7
  article-title: Evaluating a surrogate endpoint at three levels, with application to vaccine development
  publication-title: Stat Med
  doi: 10.1002/sim.3122
– year: 2004
  ident: CR22
  publication-title: Handbook of Beta Distribution and Its Applications
– volume: 90
  start-page: 107
  year: 1983
  end-page: 115
  ident: CR40
  article-title: A graded-dose study of inactivated, surface antigen influenza B vaccine in volunteers: reactogenicity, antibody response and protection to challenge virus infection
  publication-title: J Hyg (Lond)
  doi: 10.1017/S0022172400063907
– volume: 7
  start-page: 434
  year: 1998
  end-page: 455
  ident: CR21
  article-title: Alternative methods for monitoring convergence of iterative simulations
  publication-title: Journal of Computational and Graphical Statistics
  doi: 10.2307/1390675
– volume: 20
  start-page: 63
  year: 2001
  end-page: 75
  ident: CR26
  article-title: Immunologic correlates of protection induced by vaccination
  publication-title: Pediatr Infect Dis J
  doi: 10.1097/00006454-200101000-00013
– volume: 90
  start-page: 351
  year: 1983
  end-page: 359
  ident: CR33
  article-title: A comparison of live and inactivated influenza A (H1N1) virus vaccines. 1. Short-term immunity
  publication-title: J Hyg (Lond)
  doi: 10.1017/S0022172400028989
– volume: 22
  start-page: 485
  year: 2001
  end-page: 502
  ident: CR12
  article-title: Considerations in the evaluation of surrogate endpoints in clinical trials. summary of a National Institutes of Health workshop
  publication-title: Control Clin Trials
  doi: 10.1016/S0197-2456(01)00153-2
– volume: 37
  start-page: 216
  year: 2009
  end-page: 221
  ident: CR28
  article-title: On the relationship between mean antibody level, seroprotection and clinical protection from influenza
  publication-title: Biologicals
  doi: 10.1016/j.biologicals.2009.02.002
– volume: 8
  start-page: 431
  year: 1989
  end-page: 440
  ident: CR10
  article-title: Surrogate endpoints in clinical trials: definition and operational criteria
  publication-title: Stat Med
  doi: 10.1002/sim.4780080407
– volume: 13
  start-page: 177
  year: 2004
  end-page: 206
  ident: CR15
  article-title: A perspective on surrogate endpoints in controlled clinical trials
  publication-title: Stat Methods Med Res
– volume: 42
  start-page: 28
  year: 1945
  end-page: 44
  ident: CR36
  article-title: Vaccination against Influenza. A study in California during the epidemic of 1943-44
  publication-title: Am J Hyg
– volume: 49
  start-page: 159
  year: 1973
  end-page: 163
  ident: CR35
  article-title: Inactivated influenza vaccines. 2. Laboratory indices of protection
  publication-title: Postgrad Med J
  doi: 10.1136/pgmj.49.569.159
– volume: 115
  start-page: 63
  year: 2003
  end-page: 73
  ident: CR25
  article-title: Haemagglutination-inhibiting antibody to influenza virus
  publication-title: Dev Biol (Basel)
– volume: 10
  start-page: 325
  year: 2000
  end-page: 337
  ident: CR20
  article-title: a Bayesian modelling framework: concepts, structure, and extensibility
  publication-title: Statistics and Computing
  doi: 10.1023/A:1008929526011
– volume: 90
  start-page: 351
  year: 1983
  ident: 421_CR33
  publication-title: J Hyg (Lond)
  doi: 10.1017/S0022172400028989
– volume: 11
  start-page: 167
  year: 1992
  ident: 421_CR11
  publication-title: Stat Med
  doi: 10.1002/sim.4780110204
– volume-title: Handbook of Beta Distribution and Its Applications
  year: 2004
  ident: 421_CR22
  doi: 10.1201/9781482276596
– volume: 13
  start-page: 177
  year: 2004
  ident: 421_CR15
  publication-title: Stat Methods Med Res
  doi: 10.1191/0962280204sm362ra
– volume: 8
  start-page: 431
  year: 1989
  ident: 421_CR10
  publication-title: Stat Med
  doi: 10.1002/sim.4780080407
– volume: 367
  start-page: 1657
  year: 2006
  ident: 421_CR31
  publication-title: Lancet
  doi: 10.1016/S0140-6736(06)68656-X
– volume: 64
  start-page: 583
  year: 2002
  ident: 421_CR23
  publication-title: Journal of the Royal Statistical Society, Series B (Statistical Methodology)
  doi: 10.1111/1467-9868.00353
– volume: 20
  start-page: 63
  year: 2001
  ident: 421_CR26
  publication-title: Pediatr Infect Dis J
  doi: 10.1097/00006454-200101000-00013
– volume: 79
  start-page: 321
  year: 1977
  ident: 421_CR43
  publication-title: J Hyg (Lond)
  doi: 10.1017/S0022172400053158
– volume-title: EMEA
  year: 1997
  ident: 421_CR3
– volume: 55
  start-page: 1
  year: 1952
  ident: 421_CR42
  publication-title: Am J Hyg
– volume: 26
  start-page: 3516
  year: 2008
  ident: 421_CR17
  publication-title: Vaccine
  doi: 10.1016/j.vaccine.2008.04.016
– volume: 82
  start-page: 528
  year: 1987
  ident: 421_CR19
  publication-title: J Am Stat Assoc
  doi: 10.1080/01621459.1987.10478458
– volume: 42
  start-page: 28
  year: 1945
  ident: 421_CR36
  publication-title: Am J Hyg
– volume: 42
  start-page: 57
  year: 1945
  ident: 421_CR8
  publication-title: Am J Hyg
– volume: 116
  start-page: 425
  year: 1966
  ident: 421_CR38
  publication-title: J Infect Dis
  doi: 10.1093/infdis/116.4.425
– volume: 48
  start-page: 201
  year: 1975
  ident: 421_CR37
  publication-title: Yale J Biol Med
– volume: 2
  start-page: 386
  year: 2008
  ident: 421_CR18
  publication-title: The annals of applied statistics
  doi: 10.1214/07-AOAS132
– volume: 90
  start-page: 361
  year: 1983
  ident: 421_CR34
  publication-title: J Hyg (Lond)
  doi: 10.1017/S0022172400028990
– volume-title: Factsheet number 211
  year: 2008
  ident: 421_CR1
– volume: 7
  start-page: 434
  year: 1998
  ident: 421_CR21
  publication-title: Journal of Computational and Graphical Statistics
  doi: 10.2307/1390675
– volume: 115
  start-page: 63
  year: 2003
  ident: 421_CR25
  publication-title: Dev Biol (Basel)
– volume: 196
  start-page: 1304
  year: 2007
  ident: 421_CR14
  publication-title: J Infect Dis
  doi: 10.1086/522428
– volume: 1
  start-page: 49
  year: 2000
  ident: 421_CR13
  publication-title: Biostatistics
  doi: 10.1093/biostatistics/1.1.49
– volume: 4
  start-page: e218
  year: 2007
  ident: 421_CR9
  publication-title: PLoS Med
  doi: 10.1371/journal.pmed.0040218
– volume: 165
  start-page: 1366
  year: 1957
  ident: 421_CR32
  publication-title: J Am Med Assoc
  doi: 10.1001/jama.1957.02980290006002
– volume: 100
  start-page: 209
  year: 1974
  ident: 421_CR41
  publication-title: Am J Epidemiol
  doi: 10.1093/oxfordjournals.aje.a112029
– volume: 90
  start-page: 107
  year: 1983
  ident: 421_CR40
  publication-title: J Hyg (Lond)
  doi: 10.1017/S0022172400063907
– volume-title: Advanced laboratory technicals for immunological diagnostic
  year: 1975
  ident: 421_CR2
– volume: 116
  start-page: 228
  year: 1982
  ident: 421_CR39
  publication-title: Am J Epidemiol
  doi: 10.1093/oxfordjournals.aje.a113408
– volume: 103
  start-page: 125
  year: 2004
  ident: 421_CR30
  publication-title: Virus Res
  doi: 10.1016/j.virusres.2004.02.024
– volume: 27
  start-page: 4758
  year: 2008
  ident: 421_CR7
  publication-title: Stat Med
  doi: 10.1002/sim.3122
– volume: 49
  start-page: 159
  year: 1973
  ident: 421_CR35
  publication-title: Postgrad Med J
  doi: 10.1136/pgmj.49.569.159
– volume: 22
  start-page: 485
  year: 2001
  ident: 421_CR12
  publication-title: Control Clin Trials
  doi: 10.1016/S0197-2456(01)00153-2
– volume: 37
  start-page: 216
  year: 2009
  ident: 421_CR28
  publication-title: Biologicals
  doi: 10.1016/j.biologicals.2009.02.002
– volume: 176
  start-page: 6333
  year: 2006
  ident: 421_CR27
  publication-title: J Immunol
  doi: 10.4049/jimmunol.176.10.6333
– volume: 12
  start-page: 167
  year: 1994
  ident: 421_CR29
  publication-title: Vaccine
  doi: 10.1016/0264-410X(94)90056-6
– volume: 70
  start-page: 767
  year: 1972
  ident: 421_CR5
  publication-title: J Hyg (Lond)
  doi: 10.1017/S0022172400022610
– volume: 25
  start-page: 1485
  year: 2006
  ident: 421_CR16
  publication-title: Stat Med
  doi: 10.1002/sim.2282
– volume: 15
  start-page: 962
  year: 1997
  ident: 421_CR24
  publication-title: Vaccine
  doi: 10.1016/S0264-410X(96)00302-7
– volume: 21
  start-page: 1786
  year: 2003
  ident: 421_CR4
  publication-title: Vaccine
  doi: 10.1016/S0264-410X(03)00073-2
– volume: 103
  start-page: 133
  year: 2004
  ident: 421_CR6
  publication-title: Virus Res
  doi: 10.1016/j.virusres.2004.02.025
– volume: 10
  start-page: 325
  year: 2000
  ident: 421_CR20
  publication-title: Statistics and Computing
  doi: 10.1023/A:1008929526011
– reference: 15088777 - Dev Biol (Basel). 2003;115:63-73
– reference: 9261942 - Vaccine. 1997 Jun;15(9):962-7
– reference: 16158409 - Stat Med. 2006 May 15;25(9):1485-97
– reference: 17979212 - Stat Med. 2008 Oct 15;27(23):4758-78
– reference: 2727467 - Stat Med. 1989 Apr;8(4):431-40
– reference: 17579511 - PLoS Med. 2007 Jun;4(6):e218
– reference: 1579756 - Stat Med. 1992 Jan 30;11(2):167-78
– reference: 6822725 - J Hyg (Lond). 1983 Feb;90(1):107-15
– reference: 15163501 - Virus Res. 2004 Jul;103(1-2):133-8
– reference: 8147099 - Vaccine. 1994 Feb;12(2):167-74
– reference: 12686095 - Vaccine. 2003 May 1;21(16):1786-8
– reference: 13475045 - J Am Med Assoc. 1957 Nov 16;165(11):1366-73
– reference: 18495303 - Vaccine. 2008 Jun 25;26(27-28):3516-21
– reference: 16670345 - J Immunol. 2006 May 15;176(10):6333-9
– reference: 19268607 - Biologicals. 2009 Aug;37(4):216-21
– reference: 169640 - Yale J Biol Med. 1975 Jul;48(3):201-9
– reference: 12933525 - Biostatistics. 2000 Mar;1(1):49-67
– reference: 16714186 - Lancet. 2006 May 20;367(9523):1657-64
– reference: 4479059 - Am J Epidemiol. 1974 Sep;100(3):209-15
– reference: 6863909 - J Hyg (Lond). 1983 Jun;90(3):351-9
– reference: 15163500 - Virus Res. 2004 Jul;103(1-2):125-32
– reference: 4803439 - Postgrad Med J. 1973 Mar;49(569):159-63
– reference: 6863910 - J Hyg (Lond). 1983 Jun;90(3):361-70
– reference: 19079758 - Ann Appl Stat. 2008 Mar;2(1):386-407
– reference: 5928620 - J Infect Dis. 1966 Oct;116(4):425-8
– reference: 11578783 - Control Clin Trials. 2001 Oct;22(5):485-502
– reference: 17922394 - J Infect Dis. 2007 Nov 1;196(9):1304-12
– reference: 4509641 - J Hyg (Lond). 1972 Dec;70(4):767-77
– reference: 270523 - J Hyg (Lond). 1977 Dec;79(3):321-32
– reference: 11176570 - Pediatr Infect Dis J. 2001 Jan;20(1):63-75
– reference: 15198486 - Stat Methods Med Res. 2004 Jun;13(3):177-206
– reference: 14885161 - Am J Hyg. 1952 Jan;55(1):1-11
– reference: 7114034 - Am J Epidemiol. 1982 Aug;116(2):228-42
SSID ssj0017836
Score 2.4407172
SecondaryResourceType review_article
Snippet Background Antibodies directed against haemagglutinin, measured by the haemagglutination inhibition (HI) assay are essential to protective immunity against...
Antibodies directed against haemagglutinin, measured by the haemagglutination inhibition (HI) assay are essential to protective immunity against influenza...
Background Antibodies directed against haemagglutinin, measured by the haemagglutination inhibition (HI) assay are essential to protective immunity against...
Abstract Background: Antibodies directed against haemagglutinin, measured by the haemagglutination inhibition (HI) assay are essential to protective immunity...
Abstract Background Antibodies directed against haemagglutinin, measured by the haemagglutination inhibition (HI) assay are essential to protective immunity...
SourceID doaj
unpaywall
pubmedcentral
proquest
gale
pubmed
crossref
springer
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 18
SubjectTerms Adult
Antibodies
Antibodies, Viral - blood
Bayes Theorem
Bayesian statistical decision theory
Censorship
Diagnosis
Drug therapy
Health aspects
Health Sciences
Hemagglutinins - immunology
Humans
Illnesses
Immunization
Influenza
Influenza, Human - immunology
Medicine
Medicine & Public Health
Methods
Models, Theoretical
Mortality
Pandemics
Properties
Research Article
Statistical Theory and Methods
Statistics for Life Sciences
Theory of Medicine/Bioethics
Vaccination
Vaccines
Viral antibodies
Writing
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Jb9QwFLZQDywHxE5oQT4gQQ-hiR0nNreCqCqkcqJSb5bXmUjTzIjOCA1_iT_Je4knnQFVvXAcL1L8_Pkt8zZC3nrulOch5JxFmwP3q3LJQpVbzm1ZGMzOREPx7Ft9el59vRAXW62-MCZsKA88EO6IKWANAr1jkVXGWQlPNPiqqaJztS_7NN9Cqo0xlfwHmJvQ5xU1Zc6YlKmoTynro3EMORD2-tiSR33Z_n-Z85Z0-jtycnSfPiD3Vt3CrH-a2WxLQp08Ig-TakmPhyM9JndC94TcPUvO86fk9xj4Nm0XNAVo0akJl2YyQQAOfwzmbTdtbYvh0BTI3tq5X1PAFNjl8NvTTS4lTSUeYAs1E9OCnknboeXJL_OR-utopH7blqecziM11Jp1wAxOCtLSA6dOkSW0783zjJyffPn--TRPvRpyVwu1zMtopDe-tkXTmMILY4UVpYsuyOh8MMxzq0A7iw4rAPoyiKpywkWjQGEDEcmfk71u3oWXhHLmrQfVxNjoK9aUBqRrJVXhojBSiSIjHzY3pl0qZI79NGa6N2hkrfGKNV5xPyIz8n7csBhqeNy89BNCYFyGxbf7AYCkTpDUt0EyI-8QQBpZBHyYMynTAY6Hxbb0MahkYNYKBSsPdlbC03Y70_sbCOrEWq60KoWsQckrM0LHWdyI0XJdmK-udMO5rNFjnpEXA17HAzG08ZWEmWYHyTsn3p3p2mlfdpyBct4ULCOHG8xff9SN5DwcH8VtpH_1P0i_T-4P4R08L-QB2Vv-WIXXoDUu7ZueQfwBk71p6w
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: ProQuest Central
  dbid: BENPR
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhV3da9RAEF_qFfx4EL-qsVX2QdA-xCa72WQjiLTSUoQrIhb6FvYrd4EzOds75PyX_CedSTbpnVJ9vOzusZuZnY_MzG8IeWW5yS13LuSs1CFIvySUzCWh5lzHkcLqTHQUx2fp6Xny6UJcbJFxXwuDaZW9TGwFtW0MfiM_yGMhU9Bt8Yf59xCbRmFwte-goXxnBfu-RRi7RbYZAmONyPbR8dnnL0NYAUsWPL5PLNODGPYWMiZbgFNs-7GmmloE_7_l9Jqi-jOJcoik3iN3lvVcrX6o2WxNWZ08IPe9lUkPO7Z4SLZc_YjcHvs4-mPya8iBm1Zz6nO16FS5b2oyQV7svhGGVT2tdIWZ0RQoUOnGriiwF7jo8NvSvqySerQHWELVRFVgctKq637yU72j9joxqV22FjSnTUkV1WrlsJiTguK0ILR9kglt2_Q8Iecnx18_noa-bUNoUpEvwrhU0iqb6ijLVGSF0kKL2JTGydJYp5jlOgcylQbBAG3sRJIYYUqVg-0G2pLvkFHd1O4ZoZxZbcFKUbq0CctiBWRNZB6ZUiiZiyggb3uKFcZjmmNrjVnR-jYyLZDEBZK4fSID8mZYMO_gPG6eeoQsMExDHO72QXM5Kfy1LlgOiktg7LZkiTJaggJxNsmS0pjU4p-8RgYqUFrAxozyRQ9wPMTdKg7BOgMPV-Qwc29jJtxyszG827Ng4aXMVTHciYDQYRQXYuJc7ZrlVZFxLlMMngfkacevw4EYuvu5hJFsg5M3Trw5UlfTFoGcgZ2eRSwg-z3PX2_qxte5P1yK_7365_887C6526Vw8DCSe2S0uFy6F2AZLvRLf99_A1-fZSc
  priority: 102
  providerName: ProQuest
– databaseName: Springer Nature Open Access Journals
  dbid: C6C
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lb9QwELagSFAOiDehBfmABD2EJnacONxKRVUhlROVerP83I20ZFd0V9Xyl_iTzCTedANUiGNsTxTb43lkZj4T8sZxWzvufcpZMClIvyKVzBep4dzkmcbqTHQUz76Up-fF5wtxEUGSsBZmO36fy_IwB_KUMdlhkObyNrkDGqrsorLl8RAuwFKEiNvzF6KRyumQ-f-Uv1sK6PfkyCFCep_cW7ULvb7Ss9mWEjp5SB5E65Ee9dv9iNzy7WNy9yzGx5-Qn0Nu27RZ0JiDRafaf9OTCfJY_-8vbdppYxrMeKawso2ZuzUFtgHXG54d3ZRL0ojiACRUT3QDpiRt-ltNfugP1F0nHHVkW8FwOg9UU6PXHos0KShEB8I4Jo_Q7vqdp-T85NPX49M0XseQ2lLUyzQPWjrtSpNVlc6c0EYYkdtgvQzWec0cNzUYYMEiyJ_LvSgKK2zQNdhkoAX5M7LTzlv_glDOnHFgfWgTXMGqXIMCLWSd2SC0rEWWkPebHVM2YpXjlRkz1fksslS4xQq3uGuRCXk3ECx6mI6bh35EFhiGIb521wBsp-JxVawGhSQwJhtYoa2RoBi8K6oiWFs6fMlbZCCFUgA-zOpYzADTQzwtdQRWF3iuooaR-6ORcHrtqHtvw4IqSo9LVedClmDH5QmhQy8SYkJc6-erS1VxLksMiifkec-vw4QYuvG1hJ5qxMmjGY972mbaIYszsL-rjCXkYMPz1x9143IeDIfiX0v_8j_eu0d2-0QNnmZyn-wsv6_8K7D_luZ1d_Z_AdKkVi0
  priority: 102
  providerName: Springer Nature
– databaseName: Unpaywall
  dbid: UNPAY
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9NAEF6VVOJx4FkgtKA9IEEPTu1dr73mFhBVhdTCgUrlZO0zsUjtKE2E0r_En2TWXrtxoUJIHOOddfYxOw_vzDcIvdZUZZoaE1BiZQDSLw44MXEgKZVRKFx2pnMUj0-So9P40xk720Kf21wYea5AC4Cn2RRQrmajzTT0WZPl4KoomMXBXNvm0PPkIIK_CQjhNVZpxG-h7YSBcT5A26cnX8bf6hwjT-EBfv7Qq6ebagj_3wX1hqa6HkXZXaXeQ3dW5Vysf4jZbENbHT5A83aeTZDK99FqKUfq8hoE5H9ciIfovrds8bhhxUdoy5SP0e1jf3f_BP3s4u6mxRz7-DA8FeZcTCaO_5vvkkFRTgtZuGhsDLteyEqvMbA0jBF-a9ymcmKPMAFdsJiIAsxcXDQVVy7FO6yvgqHqbhsX9biyWGAp1sYlkGJQ1hoUhQ9swXVpoB10evjx64ejwJeKCBTs8zKIrOBa6ESGaSpCzYRkkkXKKsOt0kYQTWUGxqFVDoBQR4bFsWLKigzsRdDQ9CkalFVpniNMiZYaLCMhrY5JGglQ7jHPQmWZ4BkLh2jUMkmuPI66K-cxy2t_iie524LcbUH9hA_R267DvIEQuZn0veO6jsxhf9cPqsUk96IkJxkoS-buiy2JhZIclJbRcRpbpRLtXvLG8WzuJBQMTAmfaAHTc1hf-RgsQvCqWQaUez1KkCyq17zbcn3uJdtFnkWMJ2BjRkOEu1bX0QXrlaZaXeQppTxxF_ZD9Kw5It2EiPvEkHFoSXuHpzfjfktZTGvUcwK-QRqSIdpvj9nVoG5czv3uHP5t6V_8A-0uutsEkdAg5HtosFyszEuwTZfylZc3vwCDPY3f
  priority: 102
  providerName: Unpaywall
Title Relationship between haemagglutination-inhibiting antibody titres and clinical protection against influenza: development and application of a bayesian random-effects model
URI https://link.springer.com/article/10.1186/1471-2288-10-18
https://www.ncbi.nlm.nih.gov/pubmed/20210985
https://www.proquest.com/docview/915869101
https://www.proquest.com/docview/733868065
https://pubmed.ncbi.nlm.nih.gov/PMC2851702
https://bmcmedresmethodol.biomedcentral.com/counter/pdf/10.1186/1471-2288-10-18
https://doaj.org/article/29eac57841f24acb8153ed474fcc6d18
UnpaywallVersion publishedVersion
Volume 10
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVADU
  databaseName: BioMedCentral
  customDbUrl:
  eissn: 1471-2288
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0017836
  issn: 1471-2288
  databaseCode: RBZ
  dateStart: 20010101
  isFulltext: true
  titleUrlDefault: https://www.biomedcentral.com/search/
  providerName: BioMedCentral
– providerCode: PRVAFT
  databaseName: Open Access Digital Library
  customDbUrl:
  eissn: 1471-2288
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0017836
  issn: 1471-2288
  databaseCode: KQ8
  dateStart: 20010101
  isFulltext: true
  titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html
  providerName: Colorado Alliance of Research Libraries
– providerCode: PRVAON
  databaseName: DOAJ Directory of Open Access Journals
  customDbUrl:
  eissn: 1471-2288
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0017836
  issn: 1471-2288
  databaseCode: DOA
  dateStart: 20010101
  isFulltext: true
  titleUrlDefault: https://www.doaj.org/
  providerName: Directory of Open Access Journals
– providerCode: PRVEBS
  databaseName: EBSCOhost Academic Search Ultimate
  customDbUrl: https://search.ebscohost.com/login.aspx?authtype=ip,shib&custid=s3936755&profile=ehost&defaultdb=asn
  eissn: 1471-2288
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0017836
  issn: 1471-2288
  databaseCode: ABDBF
  dateStart: 20010101
  isFulltext: true
  titleUrlDefault: https://search.ebscohost.com/direct.asp?db=asn
  providerName: EBSCOhost
– providerCode: PRVBFR
  databaseName: Free Medical Journals
  customDbUrl:
  eissn: 1471-2288
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0017836
  issn: 1471-2288
  databaseCode: DIK
  dateStart: 20010101
  isFulltext: true
  titleUrlDefault: http://www.freemedicaljournals.com
  providerName: Flying Publisher
– providerCode: PRVFQY
  databaseName: GFMER Free Medical Journals
  customDbUrl:
  eissn: 1471-2288
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0017836
  issn: 1471-2288
  databaseCode: GX1
  dateStart: 0
  isFulltext: true
  titleUrlDefault: http://www.gfmer.ch/Medical_journals/Free_medical.php
  providerName: Geneva Foundation for Medical Education and Research
– providerCode: PRVHPJ
  databaseName: ROAD: Directory of Open Access Scholarly Resources
  customDbUrl:
  eissn: 1471-2288
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0017836
  issn: 1471-2288
  databaseCode: M~E
  dateStart: 20010101
  isFulltext: true
  titleUrlDefault: https://road.issn.org
  providerName: ISSN International Centre
– providerCode: PRVAQN
  databaseName: PubMed Central
  customDbUrl:
  eissn: 1471-2288
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0017836
  issn: 1471-2288
  databaseCode: RPM
  dateStart: 20010101
  isFulltext: true
  titleUrlDefault: https://www.ncbi.nlm.nih.gov/pmc/
  providerName: National Library of Medicine
– providerCode: PRVPQU
  databaseName: Health & Medical Collection
  customDbUrl:
  eissn: 1471-2288
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0017836
  issn: 1471-2288
  databaseCode: 7X7
  dateStart: 20090101
  isFulltext: true
  titleUrlDefault: https://search.proquest.com/healthcomplete
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: ProQuest Central
  customDbUrl: http://www.proquest.com/pqcentral?accountid=15518
  eissn: 1471-2288
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0017836
  issn: 1471-2288
  databaseCode: BENPR
  dateStart: 20090101
  isFulltext: true
  titleUrlDefault: https://www.proquest.com/central
  providerName: ProQuest
– providerCode: PRVFZP
  databaseName: Scholars Portal Journals: Open Access
  customDbUrl:
  eissn: 1471-2288
  dateEnd: 20250131
  omitProxy: true
  ssIdentifier: ssj0017836
  issn: 1471-2288
  databaseCode: M48
  dateStart: 20011101
  isFulltext: true
  titleUrlDefault: http://journals.scholarsportal.info
  providerName: Scholars Portal
– providerCode: PRVAVX
  databaseName: HAS SpringerNature Open Access 2022
  customDbUrl:
  eissn: 1471-2288
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0017836
  issn: 1471-2288
  databaseCode: AAJSJ
  dateStart: 20011201
  isFulltext: true
  titleUrlDefault: https://www.springernature.com
  providerName: Springer Nature
– providerCode: PRVAVX
  databaseName: SpringerOpen Free (Free internet resource, activated by CARLI)
  customDbUrl:
  eissn: 1471-2288
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0017836
  issn: 1471-2288
  databaseCode: C6C
  dateStart: 20010112
  isFulltext: true
  titleUrlDefault: http://www.springeropen.com/
  providerName: Springer Nature
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhV1Za9tAEF6aBHo8lN5Rk5p9KLR5UKJrpVWhFNskhIJNCDW4fRF7yRa4suPYtO5f6p_sjC7bbUxfBNLuSnvM7MxoZr8h5K32Vax9Y2zfS6UNu19gc88EtvR96ToCT2eiodjrh5eD4POQDdfpgKoJvL3TtMN8UoP55PTnzeoTMPzHguF5eObCJ2zP4wVOqcv3yAGIqRjzOPSCtUsBjytU2D53NEJQYDR_YkyqvCGhCiD_f7frDXn1dyxl41B9RB4s85lY_RCTyYbMunhCHlfKJm2X1PGU3DP5M3K_V7nTn5PfTSjcOJvRKmSLjoX5LkYjJMnyV6Gd5eNMZhggTWEhMjnVKwpUBpY63Gtan66kFegDNKFiJDLQPGlWJkH5JT5QvY5PKppt-M7pNKWCSrEyeKaTgvzUsHdXsSa0yNbzggwuzr90L-0qe4OtQhYvbDcVXAsdSieKhKOZkEwyV6XK8FRpIzztyxj0tVQhJqB2DQsCxVQqYlDhQGj6L8l-Ps3NIaG-p6UGZUXIVAde5AqQtwGPHZUywWPmWOS0XrFEVdDmmGFjkhQmDg8TXO0EV7t4wi3yvmkwK1E9dlftIAk01RCOu3gwnY-SirsTLwb5xdCFm3qBUJKDHDE6iIJUqVDjS94hASVIxtAxJaqzDzA8hN9K2qCkgaHLYqh5vFUTmF1tFR_VJJjUvJLELuMhqH2uRWhTig0xfi430-VtEvk-D9GHbpFXJb02A6rJ3iLRFiVvjXi7JM_GBRC5B-p65HgWOalpft2pndN50jDF_6b-9c6-HpGHZRSHbzv8mOwv5kvzBpTDhWyRvWgYtchB57x_dQ133bDbKn60tIrtAK7XnW9QPuhftb_-AW43aDI
linkProvider Scholars Portal
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtR3JbtNAdFRaicIBsRNaYA4g6MHUHm9jpAq10KqlTYRQK_VmZnNiKdghi6rwS3wD_8Z79thNQIVTj55Nnnlv3jJvI-Sl9lWifWMcn2XSAeoXOJyZwJG-Lz1XYHQmKordXnR4Fnw6D89XyK8mFgbdKhuaWBFqXSp8I99OvJBHwNu896PvDhaNQuNqU0FD2MoKeqfKMGbjOo7N_AI0uMnO0UcA9yvGDvZPPxw6tsiAo6IwmTpeJrgWOpJuHAtXh0KGMvRUpgzPlDaCaV8msGimMHWd9kwYBCpUmUhA0gDa7sO6N8ha4AcJ6H5re_u9z19aMwaGSNh8Qh6Ptj04C4cxXiVUxTIjC6ywqhjwN19YYIx_Om22ltvbZH1WjMT8QgyHC8zx4C65Y6Vauluj4T2yYor75GbX2u0fkJ-tz90gH1HrG0YHwnwT_T7ifv0m6eTFIJc5emJTgHguSz2ngM5jM4FvTZswTmqzS8AUKvoiBxGX5nW1lR_iHdWXjlDVtAUjPS0zKqgUc4PBoxQYtQYmYZ1aaFUW6CE5uxYIPiKrRVmYJ4T6TEsNUpGQmQ5Y7Alg7AFPXJWFgieh2yFvG4ilyuZQx1Iew7TSpXiUIohTBHHVwjvkTTthVKcPuXroHqJAOwzzflcN5bifWjKSsgQYZYi24owFQkkODMvoIA4ypSKNi7xGBEqROsGPKWGDLGB7mOcr3QVpEDTqMIGRm0sjgaqope6NBgVTS9UmaXsHO4S2vTgRHfUKU84maez7PEJjfYc8rvG13RDD54WEQ0-8hMlLO17uKfJBlfGcgV4Qu6xDthqcv_ypK49zq70U_zv6p__c7AuyfnjaPUlPjnrHG-RW7T7iOy7fJKvT8cw8A6l0Kp_bu0_J1-smN78BpbSkBw
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lb9QwELagSAUOiDdLC_iABD2kTZw4cbiVhao8WnGgUm-Wn7uRluyquyu0_CX-JDOJk-4CFeKY2GPF9ngemZnPhLy0qSlt6lyUMq8jkH5ZJJjLIp2mOokVVmeio3hymh-fZR_P-XnIzZl32e5dSLKtaUCUpnpxMLO-PeIiP0hg0Igx0SCTJuI6uZGBasMLDIb5sA8iYIFCQPP5C9GGImrw-v-Uymtq6feUyT5uepvcXNYztfquJpM11XR0l9wJNiU9bJngHrnm6vtk-yREzR-Qn33G27ia0ZCZRcfKfVOjEXJe-0cwqupxpSvMg6aw3pWe2hUFZgKHHJ4t7YooacB2ABKqRqoCA5NW7V0nP9Qbai_TkBqytRA5nXqqqFYrh6WbFNSkBREdUkpocynPQ3J29P7r8DgKlzREJuflIkq8ElbZXMdFoWLLleaaJ8YbJ7yxTjGb6hLMMm8Q-s8mjmeZ4carEiw10I3pI7JVT2v3hNCUWW3BJlHa24wViQK1mokyNp4rUfJ4QPa7HZMmIJjjRRoT2XgyIpe4xRK3uHkjBuR1TzBrwTuu7voWWaDvhqjbzYvpxUiGQyxZCWqKY6TWs0wZLUBdOJsVmTcmtzjIK2QgibIBPsyoUOIA00OULXkIthj4s7yEnrsbPeFMm43mnY4FZZApc1kmXORg3SUDQvtWJMQ0udpNl3NZpKnIMVQ-II9bfu0nxNC5LwW0FBucvDHjzZa6Gjd44wys8iJmA7LX8fzlR125nHv9ofjX0j_9j3FfkO0v747k5w-nn3bIrTaTI41isUu2FhdL9wwMxIV-3oiBX7ivYWM
linkToUnpaywall http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9NAEF6VVOJx4FkgtKA9IEEPTu1dr73mFhBVhdTCgUrlZO0zsUjtKE2E0r_En2TWXrtxoUJIHOOddfYxOw_vzDcIvdZUZZoaE1BiZQDSLw44MXEgKZVRKFx2pnMUj0-So9P40xk720Kf21wYea5AC4Cn2RRQrmajzTT0WZPl4KoomMXBXNvm0PPkIIK_CQjhNVZpxG-h7YSBcT5A26cnX8bf6hwjT-EBfv7Qq6ebagj_3wX1hqa6HkXZXaXeQ3dW5Vysf4jZbENbHT5A83aeTZDK99FqKUfq8hoE5H9ciIfovrds8bhhxUdoy5SP0e1jf3f_BP3s4u6mxRz7-DA8FeZcTCaO_5vvkkFRTgtZuGhsDLteyEqvMbA0jBF-a9ymcmKPMAFdsJiIAsxcXDQVVy7FO6yvgqHqbhsX9biyWGAp1sYlkGJQ1hoUhQ9swXVpoB10evjx64ejwJeKCBTs8zKIrOBa6ESGaSpCzYRkkkXKKsOt0kYQTWUGxqFVDoBQR4bFsWLKigzsRdDQ9CkalFVpniNMiZYaLCMhrY5JGglQ7jHPQmWZ4BkLh2jUMkmuPI66K-cxy2t_iie524LcbUH9hA_R267DvIEQuZn0veO6jsxhf9cPqsUk96IkJxkoS-buiy2JhZIclJbRcRpbpRLtXvLG8WzuJBQMTAmfaAHTc1hf-RgsQvCqWQaUez1KkCyq17zbcn3uJdtFnkWMJ2BjRkOEu1bX0QXrlaZaXeQppTxxF_ZD9Kw5It2EiPvEkHFoSXuHpzfjfktZTGvUcwK-QRqSIdpvj9nVoG5czv3uHP5t6V_8A-0uutsEkdAg5HtosFyszEuwTZfylZc3vwCDPY3f
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Relationship+between+haemagglutination-inhibiting+antibody+titres+and+clinical+protection+against+influenza%3A+development+and+application+of+a+bayesian+random-effects+model&rft.jtitle=BMC+medical+research+methodology&rft.au=Coudeville%2C+Laurent&rft.au=Bailleux%2C+Fabrice&rft.au=Riche%2C+Benjamin&rft.au=Megas%2C+Fran%C3%A7oise&rft.date=2010-03-08&rft.eissn=1471-2288&rft.volume=10&rft.spage=18&rft_id=info:doi/10.1186%2F1471-2288-10-18&rft_id=info%3Apmid%2F20210985&rft.externalDocID=20210985
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1471-2288&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1471-2288&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1471-2288&client=summon